Skip to content

Study · Animal study (in vivo) · rabbit · 2023

8 results

Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppressing Th17 Cell Response.

Zhao X, Li N, Yang N, Mi B, Dang W, Sun D, Ma S, Nian H, Wei R

Investigative ophthalmology & visual science1 Aug 2023Cited by 9 (Europe PMC)

PMID37531112 (opens in a new tab)PMCIDPMC10405860 (opens in a new tab)DOI10.1167/iovs.64.11.3 (opens in a new tab)PepBankPUB-37531112
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits with autoimmune dacryoadenitis, topical rTβ4 after disease onset ameliorated ocular surface inflammation versus PBS.

    In plain wordsIn rabbits with a dry eye model, thymosin β4 eye treatment reduced eye surface inflammation compared with PBS.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseOcular surface inflammation
    Study

    rabbitn: not reported in source

    Autoimmune dacryoadenitis (Sjögren's dry eye model)
    Comparator
    PBS
    Outcome group
    Inflammation markers · Eye
    Studied dose
    Dose not stated · topical · 28 daysAs given in this study (rabbit).

    Source sentences

    Summary
    Topical administration of rTβ4 after disease onset efficiently ameliorated the ocular surface inflammation and relieved the clinical symptoms.
    1 context sentence
    Summary · context
    Rabbits were treated topically with rTβ4 or PBS solution after disease onset for 28 days, and clinical scores were determined by assessing tear secretion, break-up time, fluorescein, hematoxylin and eosin staining, and periodic acid-Schiff.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rabbits with autoimmune dacryoadenitis, topical rTβ4 after disease onset relieved clinical symptoms versus PBS.

    In plain wordsIn rabbits with a dry eye model, thymosin β4 eye treatment eased clinical signs compared with PBS.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseClinical symptoms
    Study

    rabbitn: not reported in source

    Autoimmune dacryoadenitis (Sjögren's dry eye model)
    Comparator
    PBS
    Outcome group
    Inflammation markers · Eye
    Studied dose
    Dose not stated · topical · 28 daysAs given in this study (rabbit).

    Source sentences

    Summary
    Topical administration of rTβ4 after disease onset efficiently ameliorated the ocular surface inflammation and relieved the clinical symptoms.
    1 context sentence
    Summary · context
    Rabbits were treated topically with rTβ4 or PBS solution after disease onset for 28 days, and clinical scores were determined by assessing tear secretion, break-up time, fluorescein, hematoxylin and eosin staining, and periodic acid-Schiff.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rabbit lacrimal glands, rTβ4 significantly inhibited expression of Th17-related genes (RORC, IL-17A, IL-17F, IL-1R1, IL-23R and GM-CSF).

    In plain wordsIn rabbits, thymosin β4 lowered the activity of genes tied to Th17 immune cells in tear glands.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseTh17-related gene expression in lacrimal glands
    Study

    rabbitn: not reported in source

    Autoimmune dacryoadenitis (Sjögren's dry eye model)
    Comparator
    PBS
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · topical · 28 daysAs given in this study (rabbit).

    Source sentences

    Summary
    Further analysis revealed that rTβ4 treatment significantly inhibited the expression of Th17-related genes (RORC, IL-17A, IL-17F, IL-1R1, IL-23R, and granulocyte-macrophage colony-stimulating factor) and IL-17 protein in lacrimal glands, and meanwhile decreased the inflammatory mediators expression.
    1 context sentence
    Summary · context
    Rabbits were treated topically with rTβ4 or PBS solution after disease onset for 28 days, and clinical scores were determined by assessing tear secretion, break-up time, fluorescein, hematoxylin and eosin staining, and periodic acid-Schiff.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rabbit lacrimal glands, rTβ4 significantly inhibited IL-17 protein.

    In plain wordsIn rabbits, thymosin β4 lowered the inflammation protein IL-17 in tear glands.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIL-17 protein in lacrimal glands
    Study

    rabbitn: not reported in source

    Autoimmune dacryoadenitis (Sjögren's dry eye model)
    Comparator
    PBS
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · topical · 28 daysAs given in this study (rabbit).

    Source sentences

    Summary
    Further analysis revealed that rTβ4 treatment significantly inhibited the expression of Th17-related genes (RORC, IL-17A, IL-17F, IL-1R1, IL-23R, and granulocyte-macrophage colony-stimulating factor) and IL-17 protein in lacrimal glands, and meanwhile decreased the inflammatory mediators expression.
    1 context sentence
    Summary · context
    Rabbits were treated topically with rTβ4 or PBS solution after disease onset for 28 days, and clinical scores were determined by assessing tear secretion, break-up time, fluorescein, hematoxylin and eosin staining, and periodic acid-Schiff.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rabbit lacrimal glands, rTβ4 treatment decreased the expression of inflammatory mediators.

    In plain wordsIn rabbits, thymosin β4 lowered inflammation signals in tear glands.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseInflammatory mediator expression in lacrimal glands
    Study

    rabbitn: not reported in source

    Autoimmune dacryoadenitis (Sjögren's dry eye model)
    Comparator
    PBS
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · topical · 28 daysAs given in this study (rabbit).

    Source sentences

    Summary
    Further analysis revealed that rTβ4 treatment significantly inhibited the expression of Th17-related genes (RORC, IL-17A, IL-17F, IL-1R1, IL-23R, and granulocyte-macrophage colony-stimulating factor) and IL-17 protein in lacrimal glands, and meanwhile decreased the inflammatory mediators expression.
    1 context sentence
    Summary · context
    Rabbits were treated topically with rTβ4 or PBS solution after disease onset for 28 days, and clinical scores were determined by assessing tear secretion, break-up time, fluorescein, hematoxylin and eosin staining, and periodic acid-Schiff.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rabbits with autoimmune dacryoadenitis, rTβ4 repressed the phosphorylation of STAT3.

    In plain wordsIn rabbits, thymosin β4 turned down activation of a signal protein called STAT3.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseSTAT3 phosphorylation in vivo
    Study

    rabbitn: not reported in source

    Autoimmune dacryoadenitis (Sjögren's dry eye model)
    Comparator
    PBS
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · topical · 28 daysAs given in this study (rabbit).

    Source sentences

    Summary
    Mechanistically, we demonstrated that rTβ4 repressed the phosphorylation of signal transducer and activator of transcription 3 (STAT3) both in vivo and in vitro.
    1 context sentence
    Summary · context
    Rabbits were treated topically with rTβ4 or PBS solution after disease onset for 28 days, and clinical scores were determined by assessing tear secretion, break-up time, fluorescein, hematoxylin and eosin staining, and periodic acid-Schiff.
  7. 07LabIn vitro (cells)Mechanism

    In vitro, rTβ4 repressed the phosphorylation of STAT3.

    In plain wordsIn cells, thymosin β4 turned down activation of a signal protein called STAT3.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseSTAT3 phosphorylation in vitro
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, we demonstrated that rTβ4 repressed the phosphorylation of signal transducer and activator of transcription 3 (STAT3) both in vivo and in vitro.
  8. 08LabIn vitro (cells)Mechanism

    In vitro, activating the STAT3 pathway with Colivelin partly reversed the suppressive effect of rTβ4 on IL-17 expression.

    In plain wordsIn cells, switching on STAT3 partly undid the way thymosin β4 lowered IL-17.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIL-17 suppression reversed by STAT3 activator Colivelin
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Activation of the STAT3 signal pathway by Colivelin partly reversed the suppressive effects of rTβ4 on IL-17 expression in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:32 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 01:52 UTC

    Study results updated

  3. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.